Weakening "COVID" Stocks, HLB Rises on Anticipation of "The Day"

[Seok Ji-hoen, Edaily Reporter] On the 24th, the South Korean pharmaceutical and biotech stock market saw a significant rise in vaccine-related stocks following reports that a new corona virus had been discovered in Wuhan, China.

However, as the new virus has only been confirmed in a laboratory setting and the Korea Disease Control and Prevention Agency (KDCA) emphasized that the risk of human infection and transmission should not be exaggerated and the likelihood of another pandemic appears low.

Meanwhile, HLB, which is making a second attempt to secure FDA approval for its liver cancer treatment “Rivoceranib,” saw its stock rise by more than 7% that day.